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The mechanisms that maintain human T cell memory
during normal and perturbed homeostasis are not
fully understood. The repeated induction of profound
lymphocytopenia in patients undergoing multiple
cycles of cytotoxic chemotherapy infrequently
results in severe infections with viruses controlled
by memory T cells, suggesting that some memory
T cells survive chemotherapy and restore immunity.
Here, we identified a distinct subpopulation of
memory CD8+ T cells with the ability to rapidly efflux
and survive exposure to chemotherapy drugs in vitro
and in vivo. T cells with high efflux capacity shared
expression of molecules with hematopoietic stem
cells, were quiescent in nonlymphocytopenic indi-
viduals, and were induced to proliferate in patients
rendered lymphocytopenic after chemotherapy.
Effluxing T cells differentiated into noneffluxing
subsets in response to antigen stimulation and
inflammatory signals, thereby contributing to repop-
ulation of memory cells after chemotherapy.
INTRODUCTION
A hallmark of adaptive immunity to pathogens is the establish-
ment of long-lived memory T cells that are able to rapidly
respond to reinfection and control reactivation of persistent
pathogens. After clearance of primary viral infection in mice,
CD8+ memory T cells remain for the life of the animal (Murali-
Krishna et al., 1998). In humans, memory T cells elicited in re-
sponse to smallpox vaccination persist for 75 years in the
absence of re-exposure to the virus (Hammarlund et al.,
2003). The durability of T cell memory under normal homeo-
stasis is due in part to slow cell division mediated by cytokines
such as IL-15 (Judge et al., 2002; Zhang et al., 1998), but the
mechanisms by which T cell memory is maintained when
homeostasis is perturbed by toxic environmental or iatrogenic
insults that cause lymphocytopenia have not been extensively
studied.
CD8+ memory T cells are required to control reactivations of
cytomegalovirus (CMV) and Epstein Barr virus (EBV) (Smets
et al., 2002; Walter et al., 1995). Patients with acute myeloid
leukemia (AML) receive repeated cycles of chemotherapy that
induce severe but transient lymphocytopenia, yet rarely develop834 Immunity 31, 834–844, November 20, 2009 ª2009 Elsevier Inc.clinical infection with CMV or EBV either during the lymphocyte
nadir or after recovery of lymphocyte numbers (Sung et al.,
2009). The absence of infection in AML patients undergoing
chemotherapy suggests that sufficient virus-specific memory
T cells survive chemotherapy and reconstitute functional, long-
lived immunity thereafter.
Two broad subsets of memory T cells, termed central memory
(Tcm) and effector memory (Tem) cells, have been identified
that differ in phenotype and function (Sallusto et al., 1999). In
humans, these subsets have considerable heterogeneity, which
could potentially include subpopulations that serve a distinct
role in reconstituting memory T cells after chemotherapy, analo-
gous to the reconstitution of hematopoiesis by hematopoietic
stem cells (HSCs). Themechanisms bywhich HSCs are resistant
to chemotherapy are related both to cell quiescence and the
overexpression of ATP-binding cassette (ABC)-superfamily
multidrug efflux proteins that protect cells from toxic xenobiotics
and endogenous metabolites (Chaudhary and Roninson, 1991;
Gottesman et al., 2002; Mizutani et al., 2008). We used
ABCB1-mediated efflux of the fluorescent marker rhodamine-
123 (Rh123) to determine whether CD8+ memory T cells might
employ a similar mechanism. We identified a quiescent subpop-
ulation of polyclonal memory CD8+ T cells in both Tcm and Tem
cell fractions that have high multidrug cotransporter activity and
a distinct phenotype. The effluxing CD8+ T cells contain virus-
specific cells, are induced to proliferate during lymphocytopenia,
and can self-renew and differentiate into themore prevalent non-
effluxing memory subsets. Thus, distinct CD8+ memory T cells
employ conserved resistance mechanisms utilized by stem cells
of diverse origin and exhibit a stem cell-like capacity for self-
renewal and differentiation.
RESULTS
CD8+ Virus-Specific T Lymphocytes Persist
after Cytotoxic Chemotherapy
Patients with AML treated with chemotherapy that includes
ABCB1 substrates such as daunorubicin and idarubicin develop
profound transient bone marrow hypoplasia and peripheral
lymphocyte depletion (Figure 1A) (Berman et al., 1991). These
patients rarely succumb to infection from acute or persistent
viruses, suggesting that some CD8+ memory T cells resist
chemotherapy and replenish the memory T cell pool during
lymphocyte recovery. We examined whether CD8+ T cells
specific for CMV, EBV, and influenza were present in blood ob-
tained from adults after recovery from chemotherapy that
included an ABCB1 substrate drug and induced a lymphocyte
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CMV, EBV, or influenza virus were detected at a frequency of
12.5% ± 3.9% (mean ± standard error) after brief in vitro culture
with autologous monocyte-derived dendritic cells (MoDCs)
pulsed with a pool of CMV-, EBV-, and influenza-derived
peptides (Figures 1B and 1C). What is uncertain is whether the
survival of memory cells after chemotherapy is simply stochastic
Figure 1. CD8+ Virus-Specific Memory T Cells Persist through
Profound Chemotherapy-Induced Lymphocytopenia
(A) Absolute blood lymphocyte counts (mean ± SE) of healthy donors (n = 11),
and AML patients at the lymphocyte nadir (n = 10) and after recovery (n = 9,
1 died) from anthracycline containing induction chemotherapy. Statistical
significance was determined by one-way analysis of variance (ANOVA).
(B) Cytokine flow cytometry (CFC) detects IFN-g+ CD8+ virus-specific T cells in
PBMCs obtained after completion of induction and consolidation chemo-
therapy for AML. PBMC were stimulated with a pool of antigenic peptides
from CMV, EBV, and influenza viruses (CEF) and cultured with IL-2, IL-7,
and IL-15 for 8 days. The percentage of CD8+ T cells that secrete IFN-g in
response to peptide restimulation (CEF) or without restimulation (No Ag) on
day 8 is indicated. Data are shown for a patient sample obtained 2.5 months
after chemotherapy and are representative of experiments performed in six
individuals.
(C) CFC assay for IFN-g+ CD8+ T cells specific for CMV, EBV, and influenza
(CEF) in blood obtained from six AML patients after lymphocyte recovery
from chemotherapy. The assay was performed on PBMC obtained 1.5–3
months after completing chemotherapy as described in (B). Each point repre-
sents data from an individual patient and the mean is represented by the bar.
Statistical significance was determined with the two-tailed matched paired
t test.or whether a defined subset of memory T cells might preferen-
tially resist chemotherapy.
Subsets of Tcm and Tem CD8+ TcRab+ Cells Have High
Multidrug Efflux Capacity Mediated by ABCB1
Overexpression of ABC-superfamily multidrug efflux proteins
contributes to the chemotherapy resistance of HSCs and malig-
nant cells (Gottesman et al., 2002) and might explain the persis-
tence of some CD8+ memory T cells after chemotherapy. We
used multiparameter flow cytometry to measure the capacity
of CD8+ naive (Tn), Tcm, and Tem cells from normal donors to
efflux the fluorescent substrate Rh123, which is effluxed through
the same ABC transporters that efflux drugs used to treat
leukemia (Chaudhary and Roninson, 1991; Gottesman et al.,
2002). We incorporated antibodies to CD4, TcRgd, Va24.1, and
CD16 to exclude CD4+ T cells, gd T cells, NKT cells, andNK cells,
thereby allowing selective analysis of CD8+ TcRab+ T cells, used
expression of CD95 to distinguish memory cells from Tn cells,
and used CD62L to divide memory cells into Tcm and Tem cell
subsets (Figure 1). We identified a substantial population of cells
within each of the CD8+ TcRab+ Tcm and Tem cell subsets that
effluxed Rh123 at a rate far in excess of that observed for the
majority of Tcm and Tem cells (Figure 2A). The efflux of Rh123
was blocked by the addition of vinblastine, which acts as a
competitive inhibitor of ABCB1 and ABCC1 transporters, and
by cyclosporine A andPK11195, which inhibit ABCB1 (Figure 2A)
(Schinkel and Jonker, 2003; Walter et al., 2004).
It would be advantageous if surface markers could distinguish
the subsets of Tcmand Temcells with high Rh123 efflux capacity
(termed CMhi and EMhi) from slowly effluxing memory cells
(termed CMlo and EMlo) and from Tn cells. Thus, we analyzed
the expression of cell-surface molecules that were previously
identified in microarray studies to be shared between memory
T cells and HSCs (Luckey et al., 2006) or to be differentially ex-
pressed between Tn and memory cells (Haining et al., 2008;
Holmes et al., 2005). We found that Tcm and Tem cells that
rapidly effluxed Rh123 could be distinguished from their nonef-
fluxing counterparts by coexpression of high IL-18Ra and
CD161 (Figure 2B; Figure S2A and S2B available online).
CD117 (c-kit), which is expressed on HSCs (Simmons et al.,
1994), was also expressed on a substantial fraction of CMhi and
EMhi (Figure S2C); however, IL-18Ra or CD161 detected virtually
all of the rapidly effluxing cells. A small subset of Tn cells effluxed
Rh123, but effluxwas less rapid andcomplete than that observed
for CMhi and EMhi, and the effluxing Tn cells did not have high
expression of IL-18Ra or CD161 (Figures S3A and S3B).
The specificity of the efflux pathway utilized in CMhi and EMhi
was interrogated further by measuring efflux of DiOC2(3),
a substrate that has high specificity for ABCB1, minimal speci-
ficity for ABCG2, and no specificity for ABCC1 (Minderman
et al., 1996). DiOC2(3) was rapidly effluxed by the subset of
Tcm and Tem cells that had high expression of IL-18Ra and
CD161, suggesting efflux was mediated by ABCB1 (Figure 2C).
Quantitative RT-PCR of ABC cotransporter expression in
subsets of Tcm and Tem separated on the basis of expression
of high IL-18Ra confirmed high expression of ABCB1 on the
IL-18Rahi subsets of Tcm and Tem cells compared with IL-18-
Ralo subsets (Figure 2D). These data confirmed that subsets of
Tcm and Tem identified by high expression of IL-18Ra andImmunity 31, 834–844, November 20, 2009 ª2009 Elsevier Inc. 835
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transporter.
CMhi and EMhi Are Resistant to Anthracycline
Cytotoxicity
The capacity of IL-18Rahi CD161hi Tem and Tcm cells to rapidly
efflux Rh123 and DiOC2(3) suggested that these cells may be
preferentially protected from cytotoxic chemotherapy. We
exposed PBMCs to a fluorescent anthracycline (daunorubicin)
and measured its efflux in CD8+ T cells over 30 min, using multi-
parameter flow cytometry to distinguish cells that expressed
high amounts of IL-18Ra and CD161. The IL-18Rahi and
CD161hi subsets of CD8+ Tcm and Tem cells rapidly effluxed
daunorubicin, and efflux was blocked by vinblastine, PK11195,
and cyclosporine (Figure 3A, and data not shown).
We then sort-purified IL-18Rahi and IL-18Ralo CD8+ Tcm and
Tem cells without Rh123 loading to avoid competitive antago-
nism of efflux, cultured the sorted subsets for 40 hr in the pres-
ence or absence of daunorubicin alone or with PK11195, and
evaluated apoptosis by Annexin V staining. IL-18Ralo cells in
both Tcm and Tem cell subsets were highly susceptible to
Figure 2. Subsets of Tcm and Tem Cells
Rapidly Efflux Rh123 and DiOC2(3)
(A and B) PBMCs were loaded on ice with Rh123,
cultured in medium alone (Medium) or with
ABCB1 inhibitors vinblastine (Vbl), cyclosporine
A (CyA), or PK11195, as indicated, and labeled
with mAbs. Gating is on Tcm and Tem cells iden-
tified as CD62L+ and CD62L events, respectively
within the CD4CD16TcRgdVa24CD3+CD8+
CD95+ population (Figure S1). Rh123 effluxing
cells are identified in the upper-left quadrant of
each panel. Data are representative of four sepa-
rate experiments.
(C) PBMCs were loaded on ice with DiOC2(3),
cultured in medium alone (Medium) or with
ABCB1 inhibitors as indicated, and labeled with
mAbs. Gating is on Tcm and Tem cells identified
as CD62L+ and CD62L events, respectively
within the CD4CD16TcRgdVa24CD3+CD8+
CD95+ population (Figure S1). Data are represen-
tative of four separate experiments.
(D) Quantitative RT-PCR analysis of ABC trans-
porter expression on sort-purified IL-18Rahi
CD8+ Tcm or Tem cells. Expression of ABCB1 is
normalized to that of CMhi. Data represent the
mean ± SE of three separate experiments, each
performed in triplicate.
apoptosis when cultured in daunoru-
bicin, and the addition of PK11195 only
slightly increased apoptosis. By con-
trast, the IL-18Rahi cells in both Tcm
and Tem cell subsets were remarkably
resistant to daunorubicin-induced apo-
ptosis, and resistance was abrogated
by the addition of PK11195 or cyclo-
sporine (Figure 3B, and data not shown).
Thus, the high ABCB1-mediated drug
efflux capacity of IL-18Rahi CD161hi Tem and Tcm cells confers
upon them resistance to anthracycline chemotherapy.
CMhi and EMhi Are Distinct Subsets
of Antigen-Experienced Memory T Cells
CD8+ CD161hi T cells with rapid Rh123 efflux capacity were
either undetectable or exceedingly rare in cord blood, but they
were found in all 46 adult blood samples, consistent with the
emergence of these memory cells as a consequence of antigen
exposure during the neonatal-to-adult transition (Figures 4A and
4B). The frequency of CD8+ CD161hi T cells as a component of
total CD8+ T cells was low, particularly in the CD62L+ Tcm subset
and declined steadily with age (Figure 4B). CMhi and EMhi T cells
could be distinguished from each other on the basis of the
expression of CD62L, but were otherwise similar in surface
phenotype. CD161hi CD8+ CMhi and EMhi T cells were uniformly
CD45RO+, expressed homogeneously high amounts of CD127
and CD28, and were CD27+ and CD122+. These cells expressed
low CD45RA, perforin, and granzyme A, had lower expression of
CD8a than their CD161lo counterparts, andwere CD25, CD57,
granzyme B, and PD-1 (Figures 4C and 4D).836 Immunity 31, 834–844, November 20, 2009 ª2009 Elsevier Inc.
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immunity after chemotherapy, it should be possible to derive
polyclonal virus-specific T cells from these subsets. A prior study
suggested that CD161hi CD8+ T cells were less responsive to
T cell receptor (TCR) ligation (Takahashi et al., 2006). Thus, we
examined the requirements to induce proliferation of sort-puri-
fied CMhi and EMhi T cells and confirmed these cells proliferated
poorly to CD3 monoclonal antibody (mAb, OKT3) alone, but
proliferatedwell if IL-18 or anti-CD28were added to provide cos-
timulation (Figure 5A). We then stimulated sort-purified CMhi,
EMhi, and Tn cells with autologous MoDCs that expressed
CD80 andCD86 and that were pulsedwith peptides correspond-
ing to epitopes of EBV or influenza. This assay elicited a popula-
tion of tetramer positive T cells from each of the memory subsets
in three of three donors (Figure 5B). Molecular spectratyping of
expressed TCR Vb genes was also performed for estimating
the diversity of TCR gene usage by CD8+ Tcm and Tem cell
subsets sorted on the basis of high and low CD161 expression
and Rh123 efflux and by Tn cells. CMhi and EMhi cell subsets
had less diverse TCR Vb usage than the Tn cell subset, consis-
tent with clonotype selection by prior antigen exposure.
However, the TCR Vb diversity of the CMhi and EMhi cell subsets
was broad and similar to that observed in the CMlo and EMlo
subsets (Figure S4). These data confirm that antigen-experi-
enced T cells are found in the CMhi and EMhi subsets.
CMhi and EMhi Express High bcl-2 and bcl-xL
and Have a Low Proliferative Fraction
We noted that the fraction of IL-18Rahi Tcm and Tem cells that
stained with Annexin V after culture in medium alone was signif-
icantly lower than for IL-18Ralo cells (Figure 3B). This suggested
Figure 3. CMhi and EMhi Efflux Daunorubicin and
Are Protected from Cytotoxicity during Exposure
to Daunorubicin
(A) PBMCs were loaded with daunorubicin, cultured in
medium alone or with ABCB1 inhibitors (Vbl, PK11195), and
surface-labeled with mAbs. CD8+ Tcm and Tem cells were
identified as described in Figure 2, and the subset that
effluxed daunorubicin is shown in the gate in each panel.
Data are representative of three separate experiments.
(B) Sort-purified IL-18Rahi Tcm and Tem cells are resistant to
daunorubicin in vitro. IL-18Rahi and IL-18Ralo subsets of Tcm
and Tem cells were sort purified, cultured for 40 hr in the pres-
ence or absence of daunorubicin with (black bars) or without
(white bars) PK11195, and labeled with Annexin V. Data repre-
sent the mean ± SE of four separate experiments. Statistically
significant differences were determined with the two-tailed
matched paired t test.
that factors in addition to drug efflux might
contribute to survival of IL-18Rahi CD161hi T cells
after exposure to daunorubicin. We compared
the expression of bcl-2 and bcl-xL in effluxing
Tcm and Tem cells (identified by CD161hi expres-
sion) with their noneffluxing CD161lo counterparts
and found that the CD161hi Tcm and Tem cells
constitutively expressed higher bcl-2 and bcl-xL
(Figure 6A). Cells that have a higher proliferative
rate, which can be assessed by staining of intracel-
lular Ki-67, are more sensitive to daunorubicin (Meyn et al., 1980;
Scholzen and Gerdes, 2000). The proportion of CD161hi CD8+
Tcm and Tem cells in blood that expressed Ki-67 was signifi-
cantly lower than that of CD161lo CD8+ Tcm and Tem cells
(Figure 6B). Thus, CMhi and EMhi cells are endowed with several
mechanisms including drug efflux, higher levels of antiapoptotic
molecules, and a lower cell-cycle fraction that enhances resis-
tance to cytotoxic chemotherapy.
CMhi and EMhi Proliferate in Response to Cytokines
that Maintain Lymphocyte Homeostasis
IL-7 and IL-15 promote the survival and intermittent proliferation
of T cells under normal homeostasis and drive their proliferation
during lymphocytopenia to restore homeostasis (Schluns et al.,
2000; Tan et al., 2002). To determine the responsiveness of
CMhi and EMhi subsets to IL-7 and IL-15, we sort-purified
CD161hi Rh123 effluxing and CD161lo non-effluxing Tcm and
Tem cells, labeled them with CFSE, and cultured them with
IL-7 or IL-15 in the absence of TCR ligation. A greater proportion
of CMhi underwent one or more divisions after culture in IL-7
compared to the CMlo, EMhi, and EMlo subsets, although
a substantial fraction of cells in all subsets remained undivided
(Figure 6C). Both effluxing and noneffluxing Tcm and Tem cells
proliferated vigorously in response to IL-15, demonstrating that
CMhi and EMhi cells were responsive to homeostatic cytokines
(Figure 6C).
CMhi and EMhi T Cells Are Enriched and Proliferate
in Patients Undergoing Chemotherapy for AML
On the basis of the in vitro studies, we reasoned that CMhi and
EMhi T cells might preferentially survive cytotoxic chemotherapyImmunity 31, 834–844, November 20, 2009 ª2009 Elsevier Inc. 837
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topenia when IL-7 and IL-15 are elevated (Gattinoni et al., 2005).
We first confirmed that high expression of CD161 identified the
subsets of Tcm and Tem cells that rapidly effluxed Rh123 in
chemotherapy-treated AML patients as in normal donors (data
not shown). We then used CD161 to identify CMhi and EMhi in
ten AML patients with lymphocytopenia after chemotherapy
and compared the proportion of CD161hi and CD161lo T cells
that expressed Ki-67 with that in healthy donors. We found
a dramatic increase in the proportion of CD161hi Tcm and Tem
cells that expressed Ki-67 in lymphocytopenic patients
(Figure 6D). CD161lo CD8+ memory T cells and CD161neg-int Tn
cells that survived chemotherapy were also recruited into the
cell cycle, but to a lesser extent than the CD161hi subsets. The
preferential survival of CMhi and EMhi and their recruitment into
the cell cycle during lymphocytopenia resulted in an enrichment
Figure 4. CMhi and EMhi Are Absent from
Cord Blood and Exhibit a Memory Pheno-
type
(A) Mononuclear cells from cord (n = 6) and adult
(n = 46) blood were loaded with Rh123 and
analyzed by flow cytometry as described in
Figure 2. The mean ± SE percentage of CMhi
and EMhi in the total CD8+ T cell population is
shown. Statistically significant differences were
determined with the two-tailed t test.
(B) The percentage of each subset in its parent
population is shown according to the age of the
donor. Linear regression is shown on each graph
and r2 (derived from the Pearson correlation coef-
ficient) and p values are as indicated.
(C and D) Phenotype of CD161hi Tcm and Tem
cells. PBMCs from healthy adults were surface-
labeled with antibodies to CD4, CD16, TcRgd,
Va24, CD3, CD8, CD95, and CD62L, and CD8+
Tcm and Tem cells were identified as described
in Figure 2. Expression of the indicated molecules
on the CD161hi and CD161lo CD8+ Tcm and Tem
cell subsets is shown in (C) and (D), respectively.
CMhi and EMhi cells are identified as CD161hi
events, designated by the gate on the x axis of
each plot. Data are representative of four experi-
ments.
of CD161hi Tcm and Tem cells as a
component of the total Tcm and Tem
cell subsets in AML patients as lympho-
cyte numbers recovered from chemo-
therapy (Figure 6E). Thus, the phenotyp-
ically distinct subsets of CD8+ memory
T cells with rapid efflux capacity survive
cytotoxic chemotherapy in vivo, are
induced to divide, and are enriched
during the lymphocyte nadir.
CD161hi Effluxing T Cells
Differentiate into CD161lo
Noneffluxing T Cells
The accumulation of CD161hi T cells in
the blood of AML patients after chemo-
therapy could result from the acquisition of a CD161hi phenotype
by surviving CD161lo Tcm, Tem, or Tn cells induced to proliferate
during lymphocytopenia. Thus, we cultured sort-purified, CFSE-
labeled CD161lo subsets in vitro with IL-7 and IL-15 in the
absence of a TCR signal and analyzed their phenotype during
cell division. Infrequent cells converted to a CD161hi phenotype
in CMlo (0.23% ± 0.11%, mean ± SE, n = 7), EMlo (1.78% ±
1.18%, n = 7), and Tn (0.33% ± 0.17%, n = 3) cultures, although
a subset of Tn cells acquired CD95, consistent with prior reports
that Tn cells may acquire memory markers in lymphocytopenia
(Figure 7A). CMhi and CMlo cells exhibited reduced expression
of CD62L, suggesting that CMhi and CMlo may convert to EMhi
and EMlo cells, respectively, in lymphocytopenia-induced prolif-
eration (Figure 7A). Conversion from CD161hi effluxing to
CD161lo noneffluxing subsets was not observed when prolifera-
tion was driven by cytokines alone.838 Immunity 31, 834–844, November 20, 2009 ª2009 Elsevier Inc.
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required to differentiate CD161hi Tcm and Tem cells to their
CD161lo counterparts and stimulated highly purified CMhi,
EMhi, CMlo, and EMlo cells from seven different donors with
plate-bound anti-CD3 and anti-CD28 in media with IL-7. After
11–14 days, 26.05% ± 11.39% and 9.13% ± 5.94% (mean ±
SE, n = 7) of T cells in the cultures of CMhi and EMhi cells, respec-
tively, had acquired a CD161int-neg phenotype (Figure 7B). The
proportion of cells that downregulated CD161 expression and
the degree of downregulation was greater in cultures of CMhi
than EMhi cells. However, the CD161lo T cells that emerged after
TCR and costimulatory signaling from both subsets also lost the
capacity to rapidly efflux Rh123 (Figure 7C).
We next investigated whether virus-specific T cells present in
CMhi and EMhi subsets could differentiate to CD161lo nonefflux-
ing cells in response to antigen stimulation. For these experi-
ments, sort-purified CMhi and EMhi were first cultured for 11
days in IL-7 and IL-15 to mimic conditions during recovery
from chemotherapy-induced lymphocytopenia and then stimu-
lated with autologous fibroblasts infected with CMV. After stim-
Figure 5. CMhi and EMhi Cells Proliferate to Anti-CD3 and Costimu-
lation and Harbor Virus-Specific CTLs
(A) CMhi (white bars) and EMhi (black bars) cells were sort-purified and cultured
for 3 days in wells with plate-bound anti-CD3 with or without anti-CD28 or
IL-18, and tritiated thymidine incorporation was measured for the last 18 hr.
Data show the mean ± SE of triplicate samples and are representative of
data from two donors.
(B) CMhi, EMhi, and Tn cells were sort-purified fromHLA-A*0201+ donors, stim-
ulated with autologous MoDCs pulsed with epitopes from influenza
(GILGFVFTL) or EBV (GLCTLVAML), and cultured for 8 days in the presence
of IL-2, IL-7, and IL-15. Cells were stained with anti-CD8 and HLA-A*0201
tetramers folded with the influenza or EBV peptides. The percentage of
tetramer+ events is shown. Data are representative of three (CMhi and EMhi)
or two (Tn) experiments.ulation with virus-infected fibroblasts for 8 days, virus-specific
IFN-g+ T cells were detected in CD161hi, CD161int, and
CD161neg subsets by cytokine flow cytometry (Figure 7D).
Thus, CD161hi memory CD8+ T cells that preferentially survive
chemotherapy retain the capacity to proliferate to homeostatic
cytokines, respond to antigen, and differentiate into CD161lo
subsets when provided with costimulatory and/or inflammatory
signals from virus-infected antigen-presenting cells (APCs).
The data support a role for CD161hi CD8+ T cells in maintaining
virus-specific memory after chemotherapy and repopulating
the memory compartment after recovery from lymphocytopenia.
DISCUSSION
Cytotoxic chemotherapy causes a profound reduction in neutro-
phils and platelets as a consequence of toxicity to committed
hematopoietic progenitors, and restoration of hematopoiesis
occurs because HSC are endowed with cell-intrinsic mecha-
nisms that enable their survival after drug exposure. T cell
numbers are also transiently severely depleted after chemo-
therapy, and recovery, which occurs by proliferation of residual
mature naive and memory T cells and by development of naive
T cells in the thymus, is often delayed in adults with age-related
involution of the thymus (Mackall et al., 1997).
Here, we identified a compartment of human memory CD8+
T cells in both the CD62L+ Tcm and CD62L Tem cell subsets
that shares resistance mechanisms with HSCs, including the
capacity to rapidly efflux ABCB1 substrate drugs and to prefer-
entially survive exposure to chemotherapy in vitro and in vivo.
Memory T cells with high drug efflux capacity can be distin-
guished from their noneffluxing counterparts in normal individ-
uals by the expression of higher amounts of c-kit, IL-18Ra,
CD161, bcl-2, CD28, CD127, and bcl-xL and by a low proportion
that are Ki-67+. Rapidly effluxing memory T cells are less
frequent in peripheral blood than their noneffluxing counterparts,
particularly the CMhi subset, which represents <0.05% of total
PBMCs in normal donors. CMhi and EMhi cells are quiescent
when lymphocyte numbers are normal, but are induced to prolif-
erate in patients rendered lymphocytopenic after chemotherapy,
and can acquire a noneffluxing phenotype as a consequence of
proliferation and stimulation with virus-infected APCs.
The identification of a subset of memory T cells with enhanced
resistance to chemotherapy was facilitated by drug efflux assays
that identified cells with high ABC transporter activity. Additional
molecules such as c-kit, IL-18Ra, and CD161 that are expressed
on T cells with high efflux capacity were identified by analyzing
surface expression of molecules previously shown by gene
expression arrays to be shared by hematopoietic progenitors
and memory T cells and to be differentially expressed by Tn
and memory cells. The role of CD161 in T cells is controversial
because CD161 ligation by the two known ligands, lectin-like
transcript-1 (LLT1) or proliferation-induced lymphocyte-associ-
ated receptor (PILAR), can either inhibit or augment cytokine
secretion and proliferation mediated by TCR signaling (Aldemir
et al., 2005; Huarte et al., 2008; Rosen et al., 2005; Rosen
et al., 2008). We found that effluxing CD8+ CD161+ T cells prolif-
erated poorly to anti-CD3 alone and required costimulation
through CD28 or IL-18Ra, demonstrating that these subsets
of quiescent T cells may only respond to antigen underImmunity 31, 834–844, November 20, 2009 ª2009 Elsevier Inc. 839
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lated on CD8+ T cells in the contraction phase, and incorporation
of IL-18 into a tumor vaccine promoted long-livedmemory T cells
(Haring and Harty, 2009; Luo et al., 2005). However, in IL-18Ra-
deficient and IL-18-deficient mice, no defects in CD8+ T cell
memory were apparent (Haring and Harty, 2009). Thus, addi-
tional studies will be required to determine whether IL-18
signaling serves a distinct function in human CD8 T cell memory
formation or is required for the selective derivation and/or main-
tenance of memory T cells with high drug efflux capacity.
Although differing in CD62L expression, CMhi and EMhi exhibit
a phenotype typical of memory T cells and are CD127hi, CD28hi,
CD27+, perforinlo, granzymeB, CD25, and PD-1. This pheno-
type and the absence of Ki-67 expression in CMhi and EMhi
suggest that T cells with high efflux capacity are not recently
activated and distinguishes these cells from anergic or
exhausted CD8+ T cells or those undergoing deletional tolerance
described in murine models (Haining et al., 2008; Parish et al.,
2009; Wherry et al., 2007). The TCR Vb repertoire of CMhi and
EMhi was similar in diversity to CMlo and EMlo subsets, and
T cells specific for both persistent and cleared viruses were
expanded from CMhi and EMhi subsets. The TCR diversity and
decreased frequency of CMhi and EMhi with age is evidence
that these subsets do not emerge as a consequence of age-
associated clonal expansions (Messaoudi et al., 2006).
A very low fraction of CMhi and EMhi T cells are Ki-67+ in the
blood of normal donors. In lymphocytopenic patients recovering
from chemotherapy, IL-7 and IL-15 are elevated to promote
recovery of lymphocyte numbers, and our studies showed that
CMhi and EMhi proliferate to IL-7 and IL-15 in vitro and during
Figure 6. CMhi and EMhi Are bcl-2hi, bcl-
xLhi, and Quiescent in Healthy Individuals,
but Proliferate andAre Enriched in Lympho-
cytopenia
(A) CD161hi effluxing and CD161lo noneffluxing
Tcm and Tem cells were identified in PBMCs as
described in Figure 2, and stained for intracellular
bcl-2 (upper panels) or bcl-xL (lower panels).
Mean fluorescence intensity (MFI) of bcl-2 and
bcl-xL expression in effluxing and noneffluxing
memory subsets from seven healthy individuals
are shown in the adjacent graphs. Statistically
significant differences were determined with the
two-tailed matched paired t test.
(B) CD161hi and CD161lo Tcm and Tem cells were
identified in PBMC as described in Figure 2 and
stained for intracellular Ki-67 expression. Repre-
sentative plots of Ki-67 expression on CD161hi
and CD161lo Tcm and Tem cells are shown (left
panel). The adjacent graph (right panel) shows
the mean percentage ± SE of cells that express
Ki-67 in each subset in eight healthy individuals.
Statistically significant differences were deter-
mined with one-way ANOVA.
(C) Subsets were isolated on the basis of
CD161 expression and Rh123 efflux capacity,
CFSE-loaded, and cultured with IL-7 or IL-15 for
10 days before flow cytometry analysis. Histo-
grams show viable events, gated by DAPI exclu-
sion. Data are representative of experiments
from four healthy individuals.
(D) Peripheral blood samples from AML patients
during the lymphocyte nadir after completion of
induction chemotherapy were surface-labeled
for identifying memory T cell subsets and Tn and
then intracellularly stained for Ki-67, as described
in (B). The fold increase in the percentage of Ki-
67+ events between healthy individuals (n = 8)
and AML patients after chemotherapy (n = 10)
for each subset is shown (mean ± SE). Statistically
significant differences were determined with one-
way ANOVA.
(E) The percentages of CMhi (left panels) and EMhi
(right panels) in their respective parent popula-
tions are shown at variable times after com-
mencement of anthracycline-containing induction
chemotherapy for de novo AML. Data from five individuals are shown. Bar graphs show a comparison of the mean ± SE percentages of CMhi (left) or EMhi (right)
in their parent populations between the first sample drawn after completion of anthracycline infusion (Early) and the last sample drawn before day 28 (Late).
Statistically significant differences were determined with the two-tailed matched paired t test.840 Immunity 31, 834–844, November 20, 2009 ª2009 Elsevier Inc.
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in reconstituting T cell memory after chemotherapy or other toxic
agents that induce lymphocytopenia. Conversion of T cells from
CD161lo memory and Tn cell subsets to a CD161hi phenotype
was not observed, suggesting that the accumulation of
CD161hi cells after chemotherapy reflects their higher intrinsic
resistance to cytotoxic agents and responsiveness to homeo-
static cytokines. Proliferation of CMhi and EMhi cells induced
in vitro by homeostatic cytokines alone did not result in loss of
rapid drug efflux capacity or the CD161hi phenotype, but did
result in a reduction of CD62L expression on CMhi cells and their
conversion to EMhi. However, stimulation of CMhi and EMhi with
anti-CD3 and anti-CD28 or with virus-infected APCs generated
CD161int-neg cells that had both lost CD62L and the capacity to
rapidly efflux Rh123. Cell-transfer studies with marked T cells
will be needed to definitively determine whether differentiation
of CMhi to EMhi and fromCD161hi to CD161lo subsets is unidirec-
tional and whether it would be facilitated by the identification of
similar subsets in animal models.
The mechanisms by which CD8+ T cell memory develops and
is maintained for life, particularly in long-lived primate species,
remain elusive. Murine studies have shown that the initial division
of naive CD8+ T cells is asymmetric, and the daughter cell
derived distal to the immune synapse is endowed with greater
capacity to maintain memory than its proximally derived coun-
terpart (Chang et al., 2007). Other murine studies have identified
antigen-experienced putative ‘‘memory stem cells’’ with the
capacity for self-renewal and differentiation into Tcm and Tem
cell subsets (Zhang et al., 2005) or have derived candidate
memory stem cells from naive precursors in vitro throughmanip-
ulation of Wnt signaling (Gattinoni et al., 2009). Our analysis
focused on identifying human memory T cells formed in vivo
that share properties with HSCs and other stem cells. The
CMhi cells identified on the basis of drug efflux capacity exhibit
a similar phenotype (CD45RAint-neg, CD62L+, CD127hi, CD122+,
granzyme Blo, and bcl-2hi) as the putative murine memory stem
cell and share expression of molecules with HSCs including
IL-18Ra and CD117 (c-kit). Like HSCs, CMhi and EMhi cells
survive cytotoxic chemotherapy and may play a critical role
in protection of the host from viral infection during and after
lymphocytopenia induced by chemotherapy or by exposure to
environmental toxins that may have provided the evolutionary
pressure to develop this property of T cell memory. The identifi-
cation of this discrete functional and phenotypic subset of
human CD8+ memory T cells provides insight into mechanisms
that preserve immunity when homeostasis is severely perturbed,
and tools to determine when these cells develop and how they
contribute to maintenance of T cell memory under normal
homeostasis. The results may have implications for vaccination
and adoptive immunotherapy for infectious disease and cancer,
for which a goal is the induction of long-lived memory T cells.
EXPERIMENTAL PROCEDURES
Studies were performed in accordance with guidelines established by the
Declaration of Helsinki, and approval was obtained from the Institutional
Review Board of the Fred Hutchinson Cancer Research Center.
Blood and Tissue Samples
All experiments using peripheral blood were performed with freshly drawn
samples. Peripheral blood was obtained from healthy volunteer donors and
Figure 7. CMhi and EMhi Differentiate into
CD161lo Subsets after Antigen Stimulation
(A) Sort-purified subsets were CFSE-loaded,
cultured with IL-7 and IL-15 for 11 days and then
analyzed for expression of CD161 and CD62L
(CMhi, CMlo, EMhi, and EMlo) or CD161 and
CD95 (Tn) by flow cytometry. Data are representa-
tive of experiments from three healthy individuals.
(B) Sort-purified CMhi, EMhi, CMlo, and EMlo were
cultured for 12 days with plate-bound anti-CD3
and anti-CD28, and IL-7 and then examined for
expression of CD161. Data are representative of
experiments from 7 healthy individuals.
(C) Sort-purified CMhi and EMhi were cultured with
plate-bound anti-CD3 and anti-CD28 and with
IL-7 for 12 days, loaded, allowed to efflux Rh123
over 30 min, and surface-labeled with anti-
CD161. Rh123 fluorescence was analyzed on
CD161hi cells (red histogram) and CD161lo cells
(blue histogram). Data are representative of
experiments from two healthy individuals.
(D) Sort-purified CMhi and EMhi were cultured for
11 days in IL-7 and IL-15 and then stimulated
with RV798 CMV-infected autologous fibroblasts.
After 9 days, the cultures of CMhi (left panels) and
EMhi (right panels) were restimulated with autolo-
gous fibroblasts either infected with CMV (RV798)
or mock-infected (No Ag) for 5 hr and stained for
intracellular IFN-g and anti-CD161. Data are
representative of experiments from three healthy
individuals.Immunity 31, 834–844, November 20, 2009 ª2009 Elsevier Inc. 841
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Complete blood counts and white cell differential counts were performed on
a Sysmex XE-2100. Cord blood was obtained with written informed maternal
consent.
Antibodies and Peptides
Monoclonal antibodies to the following molecules were obtained from BD
Biosciences (San Diego, CA) and used in these experiments: CD3, CD8,
CD4, CD16, TcRgd, TcRab, CD45RO, CD45RA, CD27, CD28, CD117,
CD127, CD161, bcl-2, perforin, granzyme A, granzyme B, Ki-67, and IFN-g.
Antibodies to IL-18Ra and CD95 were from eBioscience (San Diego, CA),
Va24 from Coulter Immunotech (Fullerton, CA), bcl-xL from Genetex (Irvine,
CA), and CD62L was from Biolegend (San Diego, CA). The following peptides
were obtained from Genscript, Corp. (Piscaway, NJ) at >80% purity by HPLC:
NLVPMVATV from CMV pp65, GLCTLVAML from EBV BMLF-1, and
GILGFVFTL from influenza M1. Pooled MHC class I-restricted peptides
derived from CMV, EBV, and influenza virus (CEF) and individual pools for
each virus were obtained from Panatecs (Tubingen, Germany).
Multiparametric Flow Cytometry
Rh123, DiOC2(3), and Daunorubicin Efflux Assays
Fresh, ficolled PBMC from healthy volunteer donors were loaded in efflux
buffer containing RPMI 1640 (GIBCO, Carlsbad, CA) and 1% bovine serum
albumin (Sigma-Aldrich, St. Louis, MO) with either 10 mg/ml Rh123 or 30 ng/
ml DiOC2(3) (Sigma) for 30 min on ice or with 2.5 mM daunorubicin (Sigma)
for 20 min at 37C. They were then washed and cultured for 30 min at 37C
in the presence or absence of vinblastine, PK11195, or cyclosporine A (Sigma),
as indicated, before surface labeling with appropriate antibodies. Samples for
Rh123 or DiOC2(3) efflux assays were acquired on a FACS ARIA (BD Biosci-
ences) equipped with 405 nm, 488 nm, and 633 nm lasers. Rh123 and
DiOC2(3) fluorescence were detected at 530/30 nm. Samples for daunorubicin
efflux assay were acquired on a custom LSR-II (BD Biosciences) equipped
with 405 nm, 488 nm, 532 nm, and 633 nm lasers. Daunorubicin fluorescence
was detected at 610/15 nm. Analysis was performed with FlowJo software
(Treestar, Ashland, OR).
Surface and Intracellular Labeling
PBMC were surface-labeled with antibodies for 20 min on ice. Samples for
intracellular staining were additionally fixed in Cytofix/Cytoperm before
washing, permeabilization, and antibody labeling in Perm/Wash buffer (BD
Biosciences). After washing, acquisition was performed on an LSR-II and
analyzed with FlowJo software. Within the CD4CD16TcRgdVa24
CD3+CD8+CD95+ T cell population, CMhi and EMhi subsets were identified
as CD62L+CD161hi or CD62LCD161hi events, respectively, and CMlo and
EMlo subsets were identified as CD62L+CD161lo or CD62LCD161lo events,
respectively.
Isolation of Effluxing and Noneffluxing Subsets
Effluxing and noneffluxing CD8+ T cell subsets were purified for functional and
differentiation assays with magnetic bead separation and cell sorting so that
>98% purity could be achieved. CD8+ T cells were positively selected with
CD8 Microbeads (Miltenyi Biotec), loaded with Rh123 and cultured for
30 min to allow Rh123 efflux, then labeled with fluorochrome-conjugated
antibodies to CD4, CD16, TCRgd, Va24, CD8, CD95, CD62L and CD161.
Labeled CD8+ T cells were sort-purified on a FACS ARIA into CMhi and EMhi
subsets identified as CD62L+Rh123loCD161hi and CD62L-Rh123loCD161hi re-
spectively, in the CD4-CD16-TcRgd-Va24-CD8+CD95+ population. CMlo and
EMlo subsets were identified as CD62L+Rh123hiCD161int/neg and CD62L-
Rh123hiCD161int/neg respectively, in the CD4-CD16-TcRgd-Va24-CD8+CD95+
population. Naive CD8+ T cells were identified as CD4-CD16-TcRgd-
Va24-CD8+CD95-CD62L+CD161int/neg.
Subsets for quantitative RT-PCR and the daunorubicin-induced apoptosis
assay were isolated as follows. CD8+ T cells were negatively selected using
the CD8+ T cell Isolation Kit II (Miltenyi Biotec). The CD8+ fraction was labeled
with fluorochrome-labeled streptavidin (BD Biosciences), then antibodies to
TcRgd, CD95, CD62L and IL-18Ra. CMhi and EMhi were identified as streptavi-
din-TcRgdCD95+IL-18Rahi events, either positive or negative for CD62L,
respectively. CMlo and EMlo were similarly identified as streptavidinTcRgd
CD95+IL-18Ralo events, either positive or negative for CD62L, respectively.842 Immunity 31, 834–844, November 20, 2009 ª2009 Elsevier Inc.Quantitative RT-PCR
Quantitative RT-PCR for ABCB1 expression in isolated subsets was per-
formed with a duplex PCR with sequence-specific ABCB1 and GAPDH Taq-
man probes. Total RNA was extracted with the RNeasy kit (QIAGEN), in accor-
dance with the manufacturer’s instructions, and cDNA was generated with
standard methods. The following primers and probes were used for ABCB1
quantitative PCR, as previously described (Burger et al., 2003): ABCB1-
forward, 50-GGAAGCCAATGCCTATGACTTTA-30; ABCB1-reverse, 50-GAAC
CACTGCTTCGCTTTCTG-30; ABCB1-probe, 6FAM- 50-TGAAACTGCCTCA
TAAATTTGACACCCTGG-30 TAMRA. The Predeveloped Taqman Assay
Reagent Human GAPDH (Applied Biosystems) served as an internal control.
Reactions were run in triplicate on an ABI 7900-HT Real-time PCR System
and analyzed with Sequence Detection Systems 2.2.2 software (Applied
Biosystems). Relative gene expression is calculated as the ratio of ABCB1:
GAPDH expression in each subset and normalized to that of CMhi.
Induction of Daunorubicin-Induced Apoptosis
Effluxing and noneffluxing Tcm and Tem subsets, isolated as above, were
cultured for 40–44 hr in the presence or absence of 0.1 mM daunorubicin,
with or without 50 mM PK11195. Cultures were harvested, washed twice
with cold PBS, and stained with Annexin V and DAPI before analysis.
In Vitro Culture of Viral Antigen-Specific CD8+ T Cells
Virus-specific T cell cultures were established from AML patients who were
within 80 days of completion of induction and consolidation chemotherapy.
PBMCs were pulsed with pooled CEF, CMV, EBV, or influenza peptides (Pan-
atecs) at 1 mg/ml for 2 hr, washed, and cultured with unpulsed autologous
PBMC. On days 8–10, the cultures were restimulated and analyzed by surface
staining with anti-CD8 mAb and then stained intracellularly for IFN-g.
Virus-specific CD8+ T cells were expanded from sort-purified CMhi and EMhi
subsets from healthy HLA-A*0201+ donors by culture with autologous peptide-
pulsed mature MoDCs or RV798 CMV-infected fibroblasts (Manley et al.,
2004). MoDCs were generated as previously described (Thurner et al., 1999)
and matured by culture with 2 ng/ml IL-1b, 1000 U/ml IL-6, 10 ng/ml TNFa
(all from R&D Systems), and 1000 ng/ml PGE2 (MP Biomedicals) for 48 hr,
pulsed in RPMI 1640 for 2 hr with peptides (1 mg/ml), washed, and irradiated
(3500 cGy) before use. Autologous fibroblasts were cultured and infected for
48 hr with RV798 supernatant, as previously described (Manley et al., 2004),
then irradiated (3500 cGy). CMhi, CMlo, EMhi, and EMlo subsets were plated
in 96-well plates with MoDCs or fibroblasts at a T cell:APC ratio of 4:1. All
cultures were supplemented with 10 U/ml IL-2 (Novartis), 1 ng/ml IL-7, and
1 ng/ml IL-15 (R&D Systems). Cytokine and half medium exchanges were
performed on days 3–4 and 6–7. MoDC-stimulated cultures were labeled
with DAPI (Sigma) for dead-cell exclusion and stained with CD8 antibody
and appropriate tetramers (Beckman Coulter). Cultures stimulated with
RV798-infected fibroblasts were surface-labeled with anti-CD8 and anti-
CD161, then stained for intracellular IFN-g expression.
Proliferation Assays
CFSE-dilution assays were used for assessing proliferation of isolated subsets
stimulated with cytokines. Subsets were loaded with CFSE (Molecular
Probes), cultured for 10 days in cytokines, resuspended in DAPI, and analyzed
by flow cytometry. Tritiated thymidine incorporation was used for assessing
proliferation in response to anti-CD3 stimulation. Subsets were cultured for
3 days with plate-bound anti-CD3 (1000 ng/ml) (OKT3, Ortho Biotech), with
or without anti-CD28 (5 mg/ml) (FHCRC Shared Resources), or IL-18 (80 ng/ml)
(MBL International, Woburn, MA), then pulsed overnight with 1 mCi tritiated
thymidine before harvesting and scintillation counting (Perkin Elmer).
In Vitro Culture and Differentiation
Sort-purified (>98%purity) CMhi, EMhi, CMlo, and EMlo were CFSE-labeled and
cultured for 11 days in the presence of 1 ng/ml IL-7 and 5 ng/ml IL-15, then
washed and labeled with anti-CD161 and anti-CD62L before analysis. Alterna-
tively, sort-purified subsets were cultured with plate-bound anti-CD3 and anti-
CD28, supplementedwith 0.2 ng/ml IL-7. After 6 days, cells were transferred to
new 96-well plates without anti-CD3 or anti-CD28 in medium supplemented
with IL-2 50 U/ml. On days 11–14, cells were washed, labeled with anti-
CD161, resuspended in DAPI, and analyzed. In some experiments, Rh123
Immunity
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above.
Statistical Methods
Statistical analysis was performed with Graphpad Prism 5 (Graphpad Soft-
ware). Data are shown as the mean ± SE, unless otherwise indicated. One-
way ANOVA with Bonferroni correction was used for comparison of three or
more groups in a single condition. Two-tailed paired t test was used for
comparison between matched paired groups. Correlation was estimated by
calculation of two-tailed Pearson coefficients and significance.
SUPPLEMENTAL DATA
Supplemental Data include four figures and can be foundwith this article online
at http://www.cell.com/immunity/supplemental/S1074-7613(09)00452-X.
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